Nigerian Pharma Heavyweight Fidelis Ayebae’s Fidson Healthcare Nine-Month Profit Rises 47% to N11.74bn

Fidelis Ayebae’s Fidson Healthcare Lifts Profit 47% as Currency Losses Fade

Fidson Healthcare, the Nigerian pharmaceutical manufacturer founded by Fidelis Ayebae, raised profit after tax 47 percent to N11.74 billion ($8.8 million) in the nine months to September 30, 2026. Revenue grew 21 percent to N112.61 billion ($84.8 million), and pre-tax profit rose almost 50 percent to N17.79 billion. Growth accelerated in the third quarter. Quarterly pre-tax profit more than doubled to N6.09 billion on revenue of N38.13 billion, up 25 percent.

The improvement owes as much to Nigeria’s currency as to Fidson’s operations. Net foreign-exchange losses fell to N104.28 million from N4.16 billion a year earlier. That swing of about N4 billion is equivalent to roughly two-thirds of the N5.9 billion increase in pre-tax profit. For investors and executives assessing Nigerian manufacturing, Fidson shows how strongly a stable naira feeds through to the earnings of import-dependent producers. It also shows how that benefit can mask cost pressures elsewhere in the income statement.

Fidson Healthcare Profit: The Currency Dividend

Nigeria’s pharmaceutical manufacturers buy most of their active ingredients and much of their packaging and equipment abroad, in dollars, while selling in naira. The sharp devaluation of 2023 and 2024 hit them on two fronts. Input costs rose, and companies with dollar-denominated obligations booked large translation losses.

A more stable currency reverses both effects. Fidson’s net FX loss is now negligible, and finance costs fell 27.4 percent to N3.73 billion. Together, these two lines explain most of the gap between the 25 percent growth in operating profit and the much faster growth in pre-tax earnings.

This matters for how the results should be read. Lower currency losses are real and valuable, but they represent the removal of a burden, not a new source of growth. They cannot recur on the same scale. A renewed weakening of the naira would reverse much of the benefit.

Operations Are Improving, With One Clear Weak Spot

Beneath the currency effect, the business is performing well. Gross profit rose 28.1 percent to N48.94 billion, faster than revenue. Gross margin widened to about 43.5 percent from about 41 percent a year earlier. That points to some combination of pricing power, product mix and lower imported-input costs as the naira firmed. Operating profit rose 25.4 percent to N21.24 billion.

The weak spot is overhead. Administrative expenses rose 65.8 percent to N16.42 billion, and selling and distribution costs increased 50.2 percent to N11.51 billion. Together, these lines grew at nearly three times the pace of revenue. Some of this may reflect investment in sales capacity and preparation for expanded manufacturing, as well as inflation in wages and logistics. The available figures do not show how much is investment and how much is structural cost growth. Investors will want management to explain the split.

If overhead continues to outpace revenue once the currency benefit has been fully absorbed, margin gains at the gross level will not reach the bottom line.

A Record Year in Prospect

Fidson reported record revenue of N119 billion last year. Its nine-month revenue already equals about 95 percent of that total. Unless the fourth quarter falls sharply below recent trends, 2026 will set a new record. Third-quarter revenue alone was N38.13 billion.

Investors have responded. Fidson’s shares closed at N83.50 on Tuesday, up about 67 percent this year from N50.10, and rose a further 4.4 percent to N87.15 by midday on Wednesday. Ayebae, who founded the company in 1995, has seen the value of his holding rise accordingly. It had already exceeded $21 million late last year.

The stock’s performance places Fidson 32nd on the Nigerian Exchange by year-to-date gains. That is a strong result, but not an outlier in a market where many companies are recovering from the currency shock.

Expansion Raises the Stakes

Fidson is expanding its manufacturing base, with the stated ambition of building sub-Saharan Africa’s largest drug factory. Earlier this year it sought $12.9 million in new funding and received $15.2 million in investor demand. That oversubscription signals confidence in its growth strategy.

The strategic logic is sound. Several multinational drugmakers, including GlaxoSmithKline, have reduced or ended local manufacturing in Nigeria in recent years. This has left room for domestic producers with local plants and distribution networks. A company with greater local capacity is also better placed to meet procurement preferences for domestically made medicines and to serve neighboring West African markets.

The risks are also clear. Large-scale manufacturing expansion requires sustained capital investment, a stable supply of imported ingredients and reliable power. All three depend on macroeconomic conditions outside the company’s control. Funding of the size disclosed so far is modest relative to an ambition of that scale. How Fidson finances the rest of the build-out, and at what currency exposure, will determine whether expansion strengthens or strains its balance sheet.

Why This Matters for Business Leaders

Fidson’s results carry a broader lesson for executives and investors in frontier and emerging markets. Currency stability can produce a sharp rebound in reported earnings, but the size of the rebound reveals the company’s underlying exposure as much as its strength.

When assessing companies benefiting from a currency recovery, three questions are useful:

• How much of the profit improvement comes from FX relief rather than operations? At Fidson, the currency swing was equivalent to about two-thirds of the pre-tax gain.
• Is the business improving at the gross-margin level? At Fidson, it is.
• Is overhead growing in line with revenue? At Fidson, it is not yet.

Companies that pass all three tests are better placed to sustain earnings if currency conditions deteriorate again.

Executive Takeaways

• What changed: Fidson’s currency losses nearly disappeared, lifting nine-month profit 47 percent and doubling third-quarter earnings.
• Why it matters: Nigerian manufacturers are recovering from the devaluation shock, but much of the earnings gain reflects currency relief that cannot repeat.
• What leaders should do next: Investors should focus on gross margins, overhead discipline and the financing of Fidson’s manufacturing expansion, not headline profit growth.

Fidson has moved from absorbing currency shocks to benefiting from their absence. The next phase is harder. Its earnings must grow on operational strength alone while it funds an expansion of considerable ambition. Over the next 12 to 24 months, the indicators that matter are the direction of the naira, the trend in administrative and selling costs relative to revenue, the financing structure of the planned factory and whether gross margins hold as input costs normalize. For investors, the measure of success will not be whether profit keeps rising, but whether it rises for reasons the company controls.

Have you read?
What Hungary’s Political Transformation Teaches About Leadership and Change.
Women in Power: Where Business and Political Leadership Converge.
Belize Participates in German Unity Day Celebrations in Panama.
How to Stop Bringing Workplace Stress Home.
Seven Healthy Aging Habits for Busy Women.

Follow CEOWORLD Magazine on: Google News, LinkedIn, X (Twitter), and Facebook.

Note: The views expressed are those of the authors and do not necessarily reflect those of CEOWORLD Magazine, its Editorial Board, or management. Content is provided "as is," may contain monetized links, and is not professional advice. See our Ethics & Guidelines for details. Reproduction requires prior written permission.

Contact info@ceoworld.biz for inquiries or media requests.